Literature DB >> 34678554

Modulating glutamine metabolism to control viral immuno-inflammatory lesions.

Deepak Sumbria1, Engin Berber2, Logan Miller3, Barry T Rouse4.   

Abstract

Infection of the cornea with HSV results in an immune-inflammatory reaction orchestrated by proinflammatory T cells that is a major cause of human vision impairment. The severity of lesions can be reduced if the representation of inflammatory T cells is changed to increase the presence of T cells with regulatory function. This report shows that inhibiting glutamine metabolism using 6-Diazo-5-oxo-l-norleucine (DON) administered via intraperitoneal (IP) starting 6 days after ocular infection and continued until day 15 significantly reduced the severity of herpetic stromal keratitis lesions. The therapy resulted in reduced neutrophils, macrophages as well proinflammatory CD4 Th1 and Th17 T cells in the cornea, but had no effect on levels of regulatory T cells. A similar change in the representation of inflammatory and regulatory T cells occurred in the trigeminal ganglion (TG) the site where HSV infection establishes latency. Glutamine metabolism was shown to be required for the in-vitro optimal induction of both Th1 and Th17 T cells but not for the induction of Treg that were increased when glutamine metabolism was inhibited. Inhibiting glutamine metabolism also changed the ability of latently infected TG cells from animals previously infected with HSV to reactivate and produce infectious virus. Published by Elsevier Inc.

Entities:  

Keywords:  6-Diazo-5-oxo-l-norleucine; Glutamine; HSV; Immunometabolism; Inflammation control; Latency

Mesh:

Substances:

Year:  2021        PMID: 34678554      PMCID: PMC8656366          DOI: 10.1016/j.cellimm.2021.104450

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  54 in total

1.  Antiviral effects of 6-diazo-5-oxo-L-norleucin on replication of herpes simplex virus type 1.

Authors:  J Cinatl; J U Vogel; J Cinatl; H Kabickova; B Kornhuber; H W Doerr
Journal:  Antiviral Res       Date:  1997-02       Impact factor: 5.970

2.  Protective Effects of Glutamine Antagonist 6-Diazo-5-Oxo-l-Norleucine in Mice with Alphavirus Encephalomyelitis.

Authors:  Sivabalan Manivannan; Victoria K Baxter; Kimberly L W Schultz; Barbara S Slusher; Diane E Griffin
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

3.  Glutamine-dependent α-ketoglutarate production regulates the balance between T helper 1 cell and regulatory T cell generation.

Authors:  Dorota Klysz; Xuguang Tai; Philippe A Robert; Marco Craveiro; Gaspard Cretenet; Leal Oburoglu; Cédric Mongellaz; Stefan Floess; Vanessa Fritz; Maria I Matias; Carmen Yong; Natalie Surh; Julien C Marie; Jochen Huehn; Valérie Zimmermann; Sandrina Kinet; Valérie Dardalhon; Naomi Taylor
Journal:  Sci Signal       Date:  2015-09-29       Impact factor: 8.192

Review 4.  Targeting T cell metabolism for therapy.

Authors:  David O'Sullivan; Erika L Pearce
Journal:  Trends Immunol       Date:  2015-01-15       Impact factor: 16.687

Review 5.  Role of regulatory T cells during virus infection.

Authors:  Tamara Veiga-Parga; Sharvan Sehrawat; Barry T Rouse
Journal:  Immunol Rev       Date:  2013-09       Impact factor: 12.988

6.  Neurological sequelae induced by alphavirus infection of the CNS are attenuated by treatment with the glutamine antagonist 6-diazo-5-oxo-l-norleucine.

Authors:  Michelle C Potter; Victoria K Baxter; Robert W Mathey; Jesse Alt; Camilo Rojas; Diane E Griffin; Barbara S Slusher
Journal:  J Neurovirol       Date:  2015-02-03       Impact factor: 3.739

7.  Glycolysis and glutaminolysis cooperatively control T cell function by limiting metabolite supply to N-glycosylation.

Authors:  Lindsey Araujo; Phillip Khim; Haik Mkhikian; Christie-Lynn Mortales; Michael Demetriou
Journal:  Elife       Date:  2017-01-06       Impact factor: 8.140

8.  Glutamine antagonist-mediated immune suppression decreases pathology but delays virus clearance in mice during nonfatal alphavirus encephalomyelitis.

Authors:  Victoria K Baxter; Rebecca Glowinski; Alicia M Braxton; Michelle C Potter; Barbara S Slusher; Diane E Griffin
Journal:  Virology       Date:  2017-05-19       Impact factor: 3.513

9.  Role of IL-18 induced Amphiregulin expression on virus induced ocular lesions.

Authors:  Siva Karthik Varanasi; Naveen K Rajasagi; Ujjaldeep Jaggi; Barry T Rouse
Journal:  Mucosal Immunol       Date:  2018-08-07       Impact factor: 7.313

Review 10.  Neutrophil Metabolic Shift during their Lifecycle: Impact on their Survival and Activation.

Authors:  Louise Injarabian; Anne Devin; Stéphane Ransac; Benoit S Marteyn
Journal:  Int J Mol Sci       Date:  2019-12-31       Impact factor: 5.923

View more
  4 in total

Review 1.  Controlling the Burden of COVID-19 by Manipulating Host Metabolism.

Authors:  Logan Miller; Engin Berber; Deepak Sumbria; Barry T Rouse
Journal:  Viral Immunol       Date:  2021-12-13       Impact factor: 2.257

2.  Controlling Herpes Simplex Virus-Induced Immunoinflammatory Lesions Using Metabolic Therapy: a Comparison of 2-Deoxy-d-Glucose with Metformin.

Authors:  Engin Berber; Barry T Rouse
Journal:  J Virol       Date:  2022-07-11       Impact factor: 6.549

3.  Interferon Signaling-Dependent Contribution of Glycolysis to Rubella Virus Infection.

Authors:  Erik Schilling; Maria Elisabeth Wald; Juliane Schulz; Lina Emilia Werner; Claudia Claus
Journal:  Pathogens       Date:  2022-05-03

4.  Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation.

Authors:  Qiang Yu; Honghu Tu; Xueyi Yin; Chang Peng; Chuanyun Dou; Wenhua Yang; Wenbiao Wu; Xiaotong Guan; Jia Li; Hexin Yan; Yi Zang; Haowen Jiang; Qiang Xia
Journal:  Front Immunol       Date:  2022-05-19       Impact factor: 8.786

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.